Myriad Genetics announced last week the appointment of Gary King to the newly created position of executive vice president of international operations. King will oversee Myriad's expansion into Europe and other international markets. His immediate focus will be commercializing Myriad's eight diagnostic products in major market countries of Germany, France, Italy, Spain, and the United Kingdom, the company said.
Prior to joining Myriad, King was CEO of the international biotech firm AverDx. King also served as the VP of international operations at Biosite and as division director in Japan for Guidant.